Devyn Smith | Chief Strategy Officer & Head of Operations

Devyn Smith, Chief Strategy Officer & Head of Operations, Sigilon

Devyn joined Sigilon Therapeutics in early 2017 as Chief Strategy Officer and Head of Operations. In this role, he has led the development of the corporate strategy, portfolio strategy and other key strategy elements.  In addition, he is accountable for project management, intellectual property, regulatory and quality/CMC with the focus of delivery of our portfolio goals.
Devyn joined Pfizer's Medicinal Sciences Division of R&D as Head of Business Operations & Strategy in April, 2016 overseeing both day to day business operations of the division, as well insuring implementable strategies are developed.  Medicinal Sciences encompasses the groups focused on discovery, formulation, and early manufacturing of the large molecule, small molecule, cell and gene therapy programs in Pfizer R&D.  Prior to this Devyn was Head of Strategy for the Pharmatherapeutics Division of Pfizer R&D focused on developing and implementing core strategies in Winning by Design in Small Molecules as well as optimizing the ROI on novel technology inventions.  Prior to this, Devyn was part of Pfizer's Neusentis Research Unit in the UK as Chief Operating Officer responsible for strategy, operations and implementing key strategies.  In addition, he supported the Pharmatherapeutics Global Clinical Research Organization as the Chief Operating Officer.  He joined Pfizer's Strategic Management Group in August 2009.
Prior to joining Pfizer, Devyn was a principal for The Frankel Group (a boutique management consulting firm in New York City and Cambridge).  In his consulting experience, Devyn led a wide range of projects, across multiple therapeutic areas and a host of technology platforms, including basic R&D tools, regenerative medicine, gene therapy, and macromolecules/biologic products. Client relationships have ranged from large pharma to small biotech companies. Regenerative Medicine has been an area of strong focus with over 30 engagements, several published papers, and numerous invited conference presentations. Prior to joining The Frankel Group, Devyn worked as a management consultant at Adventis Corporation focused on clients in information intensive companies.  
 Devyn received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development.  He also holds an MS in Biology from Idaho State University and a BS in Zoology from Brigham Young University.


Conference Day 1: Thursday 16th May 2019 @ 12:10

Technology and Strategy Roundtables

25 senior level tables hosted by thought leaders on key challenges and opportunities in next-generation therapeutic development. Participants are invited to join the group discussions on a topic of importance to them.· At each roundtable, the moderator will talk for 5 minutes to introduce the topic highlighting particular challenges specific to that area· The table will then move on to discussion for 25 minutes.· There will then be one rotation, giving participants the opportunity to have join two round tables in total(2 x 30-minute rotations and max 15 PAX)

Table 15: Making allogeneic cell therapy a reality

Conference Day 1: Thursday 16th May 2019 @ 14:15

In-house manufacture vs. outsourcing – why and when?

When should you think about in-house manufacture instead of outsourcing? 
last published: 21/Mar/19 09:25 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.


Erica Baeta 
+44 (0)207 092 1152


Jessica Robinson 
t/ +44 (0)207 092 1150


Issa Mauthoor 
+44 (0)207 092 1257